Histone deacetylase inhibitors as suppressors of bone destruction in inflammatory diseases

No abstract is available for this paper.

• Publication year

  2012

• Venue

  The Journal of pharmacy and pharmacology

• Publication date

  2012-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.2042-7158.2011.01421.xPMID 22571254
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis

  2012cited by this paper
• Pre-existing periodontitis exacerbates experimental arthritis in a mouse model.

  2011cited by this paper
• Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts.

  2011cited by this paper
• A review of the clinical implications of bisphosphonates in dentistry.

  2011cited by this paper
• Trichostatin Differentially Regulates Th1 and Th2 Responses and Alleviates Rheumatoid Arthritis in Mice

  2011cited by this paper
• Histone deacetylase inhibitors and periodontal bone loss.

  2011influential reference
• HDACi

  2011cited by this paper
• Inhibition of HDAC Activity by ITF2357 Ameliorates Joint Inflammation and Prevents Cartilage and Bone Destruction in Experimental Arthritis

  2011cited by this paper
• Histone deacetylase inhibitor MS‐275 stimulates bone formation in part by enhancing Dhx36‐mediated TNAP transcription

  2011cited by this paper
• Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro

  2011cited by this paper
• Histone deacetylase inhibition alters dendritic cells to assume a tolerogenic phenotype and ameliorates arthritis in SKG mice

  2011cited by this paper
• RANKL induces NFATc1 acetylation and stability via histone acetyltransferases during osteoclast differentiation.

  2011cited by this paper
• Small molecules for bone diseases

  2010cited by this paper
• Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis

  2010cited by this paper
• From bone biology to clinical outcome: state of the art and future perspectives

  2010cited by this paper
• Musculoskeletal molecular imaging: a comprehensive overview.

  2010cited by this paper
• Effect of Porphyromonas gingivalis-induced inflammation on development of rheumatoid arthritis

  2010cited by this paper
• Mechanisms and control of pathologic bone loss in periodontitis.

  2010cited by this paper
• Denosumab‐mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients

  2010cited by this paper
• Local effects of intra-articular corticosteroids

  2010cited by this paper
• Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis

  2010influential reference
• Association Between Periodontitis and Rheumatoid Arthritis

  2010cited by this paper
• Effect of Porphyromonas gingivalis-induced inflammation on the development of rheumatoid arthritis.

  2010cited by this paper
• Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.

  2009cited by this paper
• Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis.

  2009cited by this paper
• RANK(L) as a key target for controlling bone loss.

  2009cited by this paper
• Signaling networks that control the lineage commitment and differentiation of bone cells.

  2009cited by this paper
• Randomized controlled trial design in rheumatoid arthritis: the past decade

  2009cited by this paper
• Progression in early rheumatoid arthritis.

  2009cited by this paper
• The use of live-animal micro-computed tomography to determine the effect of a novel phospholipase A2 inhibitor on alveolar bone loss in an in vivo mouse model of periodontitis.

  2009cited by this paper
• Twenty bone mineral density loci identified by large-scale meta-analysis of genome-wide association studies

  2009cited by this paper
• Expression and Function of Histone Deacetylases in Rheumatoid Arthritis Synovial Fibroblasts

  2009cited by this paper
• Histone deacetylase inhibitors in inflammatory disease.

  2009cited by this paper
• Pathogenic bone loss in rheumatoid arthritis: mechanisms and therapeutic approaches

  2009cited by this paper
• The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.

  2008cited by this paper
• Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts

  2008cited by this paper
• The management of inflammation in periodontal disease.

  2008cited by this paper
• Drug Insight: aggrecanases as therapeutic targets for osteoarthritis

  2008cited by this paper
• RANK/RANKL: Regulators of Immune Responses and Bone Physiology

  2008cited by this paper
• The Management of Inflammation in Periodontal Disease

  2008cited by this paper
• How antirheumatic drugs protect joints from damage in rheumatoid arthritis.

  2008cited by this paper
• Molecular mechanisms of inflammatory bone damage: emerging targets for therapy.

  2008cited by this paper
• Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on?

  2008cited by this paper
• Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.

  2008cited by this paper
• Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis

  2008cited by this paper
• The role of histone deacetylases in asthma and allergic diseases.

  2008cited by this paper
• Histone deacetylase inhibitors: new hope for rheumatoid arthritis?

  2008cited by this paper
• Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model.

  2008cited by this paper
• Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model

  2008cited by this paper
• Inflammatory cells and bone loss in rheumatoid arthritis

  2007cited by this paper
• Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy

  2007cited by this paper
• Anti‐rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen‐induced arthritis in rodents

  2007cited by this paper
• Fracture risk with intermittent high-dose oral glucocorticoid therapy.

  2007cited by this paper
• 組蛋白去乙醯化抑制劑Suberoylanilide Hydroxamic Acid (SAHA)誘導人類口腔癌細胞凋亡機轉之研究

  2007cited by this paper
• Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients.

  2007influential reference
• Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: possible molecular target for osteoarthritis therapeutic intervention

  2007cited by this paper
• Acetylation in the regulation of metalloproteinase and tissue inhibitor of metalloproteinases gene expression.

  2007cited by this paper
• Epigenetics in inflammatory rheumatic diseases.

  2007cited by this paper
• Trichostatin A-mediated upregulation of p21WAF1 contributes to osteoclast apoptosis

  2007cited by this paper
• Emerging and future therapies for the treatment of bone loss associated with chronic inflammation

  2006cited by this paper
• Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate.

  2006influential reference
• The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants.

  2006cited by this paper
• Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.

  2006cited by this paper
• Suberoylanilide Hydroxamic Acid Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis by Suppressing Nuclear Factor-κB Activation*

  2006cited by this paper
• Trichostatin A cooperates with Fas-mediated signal to induce apoptosis in rheumatoid arthritis synovial fibroblasts.

  2006cited by this paper
• NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis.

  2006cited by this paper
• Bisphosphonate therapy in rheumatoid arthritis.

  2006cited by this paper
• Targeting histone deacetylases for the treatment of cancer and inflammatory diseases

  2006cited by this paper
• Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.

  2006cited by this paper
• Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from alpha-aminosuberic acid.

  2006cited by this paper
• Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation.

  2006cited by this paper
• Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models

  2006cited by this paper
• Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden

  2006cited by this paper
• NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis

  2006cited by this paper
• Histone Deacetylase Inhibitors Suppress the Inducibility of Nuclear Factor-κB by Tumor Necrosis Factor-α Receptor-1 Down-regulation

  2006cited by this paper
• Use of Oral Corticosteroids and Risk of Fractures

  2005cited by this paper
• Periodontitis and rheumatoid arthritis: a review.

  2005cited by this paper
• Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption

  2005cited by this paper
• Inhibition of Histone Deacetylase Suppresses Osteoclastogenesis and Bone Destruction by Inducing IFN-β Production1

  2005cited by this paper
• Tuberculosis associated with therapy against tumor necrosis factor alpha.

  2005cited by this paper
• Nonsteroidal anti-inflammatory drugs (NSAIDs) in the perioperative phase in traumatology and orthopedics effects on bone healing.

  2005cited by this paper
• Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?

  2005cited by this paper
• Osteoclast: Origin and Differentiation

  2005cited by this paper
• The use of NSAIDs in rheumatic disorders 2005: a global perspective

  2005cited by this paper
• Histone deacetylase inhibitors.

  2005cited by this paper
• Histone Deacetylase Inhibitors Promote Osteoblast Maturation

  2005cited by this paper
• Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment.

  2005cited by this paper
• Mechanisms of bone loss in rheumatoid arthritis

  2005cited by this paper
• British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments.

  2005cited by this paper
• A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs

  2005cited by this paper
• TNF-blocking agents and tuberculosis: new drugs illuminate an old topic.

  2005cited by this paper
• Inhibition of interleukin-1beta-induced cyclooxygenase 2 expression in human synovial fibroblasts by 15-deoxy-Delta12,14-prostaglandin J2 through a histone deacetylase-independent mechanism.

  2005cited by this paper
• Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists.

  2004cited by this paper
• Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.

  2004cited by this paper
• Biological agents for rheumatoid arthritis: targeting both physical function and structural damage.

  2004cited by this paper
• Regulation of bone lysis in inflammatory diseases

  2004cited by this paper
• Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysis.

  2003cited by this paper
• Osteoclast differentiation and activation

  2003cited by this paper
• Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages.

  2003cited by this paper
• A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis.

  2003cited by this paper

• Histone deacetylases and their inhibitors in inflammatory diseases.

  2024cites this paper
• Exploring the molecular mechanisms and shared potential drugs between rheumatoid arthritis and arthrofibrosis based on large language model and synovial microenvironment analysis

  2024cites this paper
• Aging: Epigenetic modifications.

  2023cites this paper
• Influence of epigenetics on periodontitis and peri-implantitis pathogenesis.

  2022cites this paper
• Modulating the Immune Response in Periodontitis

  2022cites this paper
• Inhibition of histone deacetylase 6 suppresses inflammatory responses and invasiveness of fibroblast-like-synoviocytes in inflammatory arthritis

  2021cites this paper
• Histone deacetylases 1 and 2 inhibition suppresses cytokine production and osteoclast bone resorption in vitro

  2020cites this paper
• Anti-rheumatic activity of Phenethyl isothiocyanate via inhibition of histone deacetylase-1.

  2020cites this paper
• Harnessing the HDAC–histone deacetylase enzymes, inhibitors and how these can be utilised in tissue engineering

  2019cites this paper
• Host modulation therapy with anti-inflammatory agents.

  2018cites this paper
• Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis

  2018cites this paper
• When epigenetics meets bioengineering-A material characteristics and surface topography perspective.

  2018cites this paper
• The emerging role of epigenetics in the pathogenesis of periodontitis - A review

  2016cites this paper
• The Effect of HDAC Inhibitor MI192 on Stem Cell Behaviour-The Potential of Utilising MI192 for Bone Tissue Engineering

  2016cites this paper
• Instant Relief and Long-lasting Protection

  2016cites this paper
• Histone deacetylase 3 supports endochondral bone formation by controlling cytokine signaling and matrix remodeling

  2016cites this paper
• Chromatin modifiers and histone modifications in bone formation, regeneration, and therapeutic intervention for bone-related disease.

  2015cites this paper
• The epigenetic paradigm in periodontitis pathogenesis

  2015cites this paper
• Targeting Epigenetics in the Development of New Diagnostic Applications—Lessons from Autoimmune Diseases

  2015cites this paper
• Deletion of Histone Deacetylase 7 in Osteoclasts Decreases Bone Mass in Mice by Interactions with MITF

  2015cites this paper
• Synergistic effects of dimethyloxalylglycine and butyrate incorporated into α-calcium sulfate on bone regeneration.

  2015cites this paper
• Regulation of Histone Acyltransferases and Deacetylases by Bioactive Food Compounds for the Prevention of Chronic Diseases

  2014cites this paper
• Trichostatin A enhances osteogenic differentiation through activation of ERK pathways in mouse bone marrow multipotent stromal cells

  2014cites this paper
• Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009

  2014cites this paper
• Epigenetics of Autoimmune Diseases

  2014cites this paper
• Targeting histone deacetylases to suppress bone loss in similar chronic inflammatory diseases, periodontitis and rheumatoid arthritis.

  2013cites this paper
• Histone deacetylase signaling in cardioprotection

  2013cites this paper
• Epigenetic drugs: a novel anti-aging strategy?

  2012cites this paper
• Towards isozyme-selective HDAC inhibitors for interrogating disease.

  2012cites this paper